Vorinostat
Top Cited Papers
- 1 January 2007
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 6 (1) , 21-22
- https://doi.org/10.1038/nrd2227
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanatePublished by Elsevier ,2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006
- Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90Journal of Biological Chemistry, 2005
- Immunopathogenesis and therapy of cutaneous T cell lymphomaJournal of Clinical Investigation, 2005
- Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acidNature Clinical Practice Oncology, 2005
- Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylationProceedings of the National Academy of Sciences, 2000
- A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylasesProceedings of the National Academy of Sciences, 1998
- Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.Proceedings of the National Academy of Sciences, 1996